expressed in SCLC but not in normal lung tissue. 13 Moreover, DLL3
is a downstream target of achaete-scute homologue 1 (ASCL1), 14, 15 which plays a pivotal role in neuroendocrine cell differentiation and SCLC growth. 16, 17 These findings suggest a potentially pivotal role for DLL3 in SCLC; however, little is known about DLL3 functions in SCLC. Here, we investigated the effect of DLL3 in SCLC tumorigenesis.
| MATERIAL S AND ME THODS

| Cell lines
We used 9 SCLC cell lines (SBC- were maintained in RPMI 1640 medium supplemented with 10%
FBS at 37°C and 5% CO 2 .
| Antibodies and western blot analysis
We used primary antibodies targeting DLL3 (1:750; ab103102;
Abcam, Cambridge, UK), NOTCH1 intracellular domain (NICD1;
1:500; #3608; Cell Signaling Technology, Danvers, MA, USA), NICD2
(1:5000; #5732; Cell Signaling Technology), NICD3 (1:1000; 55114- Sigma-Aldrich). Thermo Fisher Scientific) were used as controls.
| Quantitative RT-PCR
| DLL3 overexpression
The human cDNA-ORF clone of the DLL3 gene (DLL3-ORF plasmid), blank-vector (pCMV6-entry) and the transfection reagent TurboFectin After 24 hours, the transfected cells were diluted at 1:10 into 10-cm dishes, and the culture medium was replaced with complete medium containing G418 (600 μg/mL). Stable positive clones were obtained after screening with G418 (Thermo Fisher Scientific).
| Cell-proliferation assays
Anchorage-dependent and anchorage-independent cell growth were measured by MTT assay using 96-well plates with or without poly-HEMA coating at 72 hours after DLL3-siRNA transfection or at 72 hours after seeding DLL3-overexpressing cells. The MTT assay was performed according to the manufacturer's instructions (Thermo Fisher Scientific), and the light absorption was determined at 560 nm using a microplate reader (Varioskan Flash; Thermo Fisher Scientific).
| Migration and invasion assay
Cell migration and invasion assays were performed using 24-well 
| In vivo tumorigenicity
All animal husbandry procedures and experiments were per- and tumor volume (TV) was determined using the formula TV = (length) × (width) × (height)/2. 18 Control or DLL3-overexpressing cells were injected into 2 other mice, respectively, followed by resection on day 20 after injection for western blot and immunohistochemical analyses.
| Immunohistochemical staining
Dissected xenograft tumors were fixed in 10% formalin for 24 hours at room temperature, placed in 70% ethanol, embedded in paraffin, and then sectioned at a thickness of 5 μm. The sections were deparaffinized using xylene and rehydrated using graded concentrations of ethanol. For antigen retrieval, sections were placed in 10 mmol/L citrate buffer (pH 6.0) and heated in a pressure cooker.
The sections were then immersed in methanol containing 3% H 2 O 2 for 10 minutes to block endogenous peroxidase activity followed by incubation with normal goat serum to block nonspecific anti- Immunostaining was performed using the biotin-streptavidin immunoperoxidase method, with 3,3-diaminobenzidine used as the chromogen. Hematoxylin solution was used for counterstaining.
| Statistical analysis
Significant differences in means between 2 samples were analyzed using Student's t test, with the level of significance set at P < 0.05 
| RE SULTS
| DLL3 is expressed in human small cell lung cancer cell lines
We first explored the expression levels of DLL3 and its receptor NOTCH1 in 9 human SCLC cell lines. As shown in Figure 1A , DLL3 mRNA and protein were detected in all SCLC cell lines, whereas NOTCH1 protein was found only in SBC-3, SBC-5, MS-1 and H82 cells ( Figure 1B ). Because previous studies reported that NOTCH1
negatively regulates ASCL1, and that DLL3 is a target of ASCL1, 19, 20 we also determined ASCL1 levels in SCLC cell lines. ASCL1 protein was detected in H1688, H592 and H209 cells, all of which were lacking the NOTCH1 protein ( Figure 1C ).
| DLL3 downregulation attenuates the migration and invasion of small cell lung cancer cells
To Figures 2D and S1 ).
| DLL3 downregulation attenuates NOTCH1 expression
We then investigated whether DLL3 downregulation affects Interestingly, Snail protein levels were also attenuated in H82 and MS-1 cells, but changes in these levels relative to controls were not observed in H69 cells ( Figure 4B ). In addition, VIM mRNA level was upregulated by DLL3 downregulation in H82 cells, although VIM protein levels exhibited only marginal changes relative to controls ( Figure 4A,B) . Moreover, we found minimal differences in the mRNA and protein levels of other EMT markers between DLL3-downregulated cell and controls.
To explore whether DLL3 exerts its function through Snail, we transfected H82 cells with SNAI1-siRNA and verified downregulation of Snail protein levels ( Figure 4C ). We observed that Snail downregulation markedly inhibited cell migration and invasion ( Figures 4D,E and S2). Because NOTCH1 levels were attenuated following DLL3 downregulation, we evaluated H82 cell proliferation, migration and invasion following NOTCH1-siRNA transfection. We found that NOTCH1 downregulation did not affect the levels of other Notch Figure S3A-D) . In addition, NOTCH1 downregulation had no effect on Snail levels ( Figure S1E ). Because transforming growth factor-β (TGF-β)/Smad signaling plays a key role in EMT and is also related to Notch signaling and Snail, 21, [23] [24] [25] we examined the expression of phospho-Smad2, phospho-Smad3, Smad2, Smad3 and Smad4, finding that DLL3 downregulation had no effect on the protein levels in the 3 cell lines ( Figure 4F ).
| DLL3 overexpression induces small cell lung cancer-cell proliferation and migration
To confirm the tumorigenic role of DLL3 in SCLC, SBC-5 cells exhibiting low expression of DLL3 were transfected with the DLL3-expression vector, followed by verification of upregulated DLL3 mRNA and protein levels in the transfected cells ( Figure 5A ). DLL3 overexpression significantly promoted cell growth based on both anchorage-dependent and anchorage-independent proliferation observed relative to control SBC-5 cells ( Figure 5B ). In addition, cell-migration assays showed that DLL3 overexpression significantly upregulated SBC-5-cell migration ( Figure 5C ). We could not assess SBC-5 invasion, because neither the control and the DLL3-overexpressing cells stably invaded the transwell.
| DLL3 overexpression upregulates Snail expression
We then investigated whether DLL3 overexpression affects Notch signaling and EMT-marker levels. DLL3 overexpression increased NOTCH1/2/3 mRNA and protein levels and no difference was observed in ASCL1 protein levels ( Figure 5D ,E,F). DLL3 overexpression increased Snail mRNA and protein levels ( Figure 5G,H) . In addition, DLL3 overexpression downregulated CDH1 mRNA levels relative to those in control cells, and E-cadherin protein levels were undetected in SBC-5 cells ( Figure 5G,H) . Although the expression of Smad2/ Smad3 was elevated in DLL3-overexpressing SBC-5 cells as compared with control cells, phospho-Smad2/Smad3 levels were unaffected by DLL3 overexpression ( Figure 5I ).
| DLL3 overexpression promotes subcutaneous tumor growth of small cell lung cancer cells in vivo
We then investigated whether DLL3 overexpression promotes SCLC tumor growth in vivo. Tumor volumes in nude mice implanted with DLL3-overexpressing SBC-5 cells were significantly larger than those observed in control mice ( Figure 6A,B) , and we verified sustained upregulation of DLL3 protein levels in the tumors at 
| D ISCUSS I ON
In this study, we demonstrated that DLL3 regulates the proliferation, migration and invasion of SCLC cells, suggesting its role as an oncogene in SCLC. Moreover, our findings suggested a potential role for Snail in DLL3-mediated SCLC-cell migration and invasion. To the best of our knowledge, this represents the first study reporting an oncogenic function associated with DLL3 in SCLC.
We detected DLL3 mRNA and protein in all 9 SCLC cell lines to varying degrees in the present study. Immunohistochemistry to evaluate DLL3 levels in resected SCLC tissue demonstrated that 83% of SCLC patients were positive for DLL3 protein (unpublished data from our institute), which was similar to the 88% rate determined in a phase I trial of rovalpituzumab tesirine (Rova-T) 26 and 84% in a study from Japan. 27 Our results and others indicate that DLL3 is highly expressed in SCLC.
Although DLL3 is reportedly associated with NOTCH and/or ASCL1, 12, 14, 15 its role in tumorigenesis remains unknown. In the present study, we demonstrated that DLL3 overexpression promoted the growth of SCLC cells in vitro and in vivo and that DLL3 downregulation suppressed this proliferation phenotype. By contrast, a previous study reported methylation of the DLL3 promoter region in association with upregulated apoptosis in hepatocellular carcinoma cells. 23 In addition, Notch proteins reportedly play both tumor-promoting and tumor-suppressive roles depending on the tumor type. 5, 6 Therefore, it is possible that DLL3 might also exhibit a context-dependent role according to cancer type.
We observed that DLL3 overexpression increased the migra- 
Dll3
. 31 These findings, as well as our results, suggest that DLL3 is not necessarily an inhibitor of Notch signaling.
In our study, we found that DLL3 promoted SCLC-cell migration and invasion by modulating Snail expression, despite our observation of no significant alterations in E-cadherin or VIM levels.
The zinc-finger transcription factor Snail is upregulated in some solid malignancies, such as SCLC, and is associated with risks of metastasis and poor survival. 25, 32, 33 Snail is involved in EMT by downregulating the levels of epithelial molecules, such as Ecadherin, Occludin and Claudins. 25 However, Snail1 is a weaker mesenchymal promoter relative to PRRX1 and TWIST, which are transcription factors associated with EMT. in DLL3-overexpressing tumors, relative to those in control tumors on day 20 after implantation. E, Western blot analysis of protein levels of epithelial-mesenchymal transition markers in DLL3-overexpressing tumors, relative to those in control tumors on day 20 after implantation. F, Representative low-magnification and high-magnification images of xenograft tumors subjected to H&E staining and immunohistochemical staining for Snail, E-cadherin and VIM. Scale bars, 50 μm. *P < 0.05. DLL3 OE, DLL3 overexpression phenotype despite retention of the VIM and E-cadherin levels. 38 These findings suggest that Snail associated with DLL3 regulation itself might induce migration or invasion independent of EMT induction and without affecting the expression of EMT markers, including E-cadherin and VIM.
Snail is regulated by various complex signals, such as those associated with TGF-β signaling. 21, 24, 25 Although the expression of Smad2/Smad3 was elevated in DLL3-overexpressing SBC-5 cells as compared with control cells, phospho-Smad2/Smad3 levels were unaffected by DLL3 overexpression. Moreover, DLL3 downregulation had no effect on the Smad protein levels in H69, H82 and MS-1 cells, indicating that TGF-β signaling might have little impact on DLL3-mediated regulation. In addition to TGF-β signaling, Notch reportedly involved in crosstalk with pathways associated with mitogen-activated protein kinases (MAPK), phosphatidylinositol 3-kinase (PI3-K) and/or NF-κB pathway, which also regulate Snail. 21, 24, 25, 39 Therefore, these other Notch-related pathways might also affect Snail regulation. Further investigation is necessary to elucidate the precise mechanism associated with DLL3-Snail signaling in SCLC.
In conclusion, we identified DLL3 as a regulator of SCLC-cell proliferation, migration and invasion and an oncogene associated with modulating Snail expression. Our findings suggested that DLL3 might represent a therapeutic target for SCLC, especially in metastatic or recurrent cases.
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